Amgen
Search results
Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while ...
Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while ...
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.
4 days ago · Biogen Pharmach Share Price: Find the latest news on Biogen Pharmach Stock Price. Get all the information on Biogen Pharmach with historic price charts for NSE / BSE.
Jan 31, 2024 · Biogen will focus on LEQEMBI® (lecanemab-irmb) with Eisai and advancing potential new modalities to address the multiple pathologies of the disease and unmet patient needs. A plan for patients participating in clinical trials or on commercially available treatment is in place.
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our...
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient’s lives and to create value for shareholders and our communities.
Get the latest Biogen Inc (BIIB) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
Jun 8, 2021 · U.S. regulators on Monday approved Biogen Inc's (BIIB.O) aducanumab as the first treatment to attack a likely cause of Alzheimer's disease despite controversy over whether the clinical evidence...
FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease. June 3, 2024. Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of Accessible Air Travel. May 30, 2024.
